OncoGenex Technologies and Isis Pharmaceuticals announced encouraging preliminary data from an ongoing Phase II clinical trial of OGX-011 in combination with second-line chemotherapy in patients with metastatic hormone refractory prostate cancer. All patients had progressive disease on or within six months of first-line docetaxel therapy. Patients receiving the combination of OGX-011 and re-treatment with docetaxel in the second-line setting are achieving longer survival, longer progression-free survival and more frequent prostate-specific antigen decreases than patients treated with OGX-011 in combination with mitoxantrone, a standard second-line chemotherapeutic agent. Release [1]
Links:
[1] http://www.fiercebiotech.com/press-releases/press-release-oncogenex-isis-report-encouraging-interim-phase-ii-data-advanced-prosta